Sign In
Buy XFOR
$4.04
-0.0700 (-1.70%)
At Close: Jun 02, 2026
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
08:00am, Wednesday, 28'th Aug 2024
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management wi
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
09:30am, Saturday, 10'th Aug 2024
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Dan Ferry - IR Paula Ragan - CEO Adam Mostafa - CFO Mark Baldry - CCO Conference
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
06:01am, Thursday, 08'th Aug 2024
First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected i
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 01'st Aug 2024
BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
06:17pm, Tuesday, 02'nd Jul 2024
X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is target
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Jun 2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on
Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia Webcast to include interim hematological results from a
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
08:00am, Monday, 13'th May 2024
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management wil
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
06:01am, Tuesday, 07'th May 2024
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 01'st May 2024
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
08:00am, Tuesday, 30'th Apr 2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it wil
X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside
05:02pm, Monday, 29'th Apr 2024
X4 Pharmaceuticals, Inc. received FDA approval for mavorixafor in WHIM syndrome, along with a priority review voucher (typically worth $100M). X4 Pharmaceuticals has announced very premium pricing con
US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease
06:37am, Monday, 29'th Apr 2024
The U.S. FDA has approved X4 Pharmaceuticals' drug to treat a rare genetic immunodeficiency disease, the company said on Monday.
